Search Clinical Trials
Sponsor Condition of Interest |
---|
Understanding Immunology and Patient Outcomes of COVID-19 in Hospitalized Patients
University of Vermont
Covid19
The adaptive immune response, consisting of antiviral T and B cells, is critical for
providing protection against viruses such as SARS-CoV-2, both during an active infection and
later following a subsequent exposure. They can both also potentially contribute to
pathogenesis... expand
The adaptive immune response, consisting of antiviral T and B cells, is critical for providing protection against viruses such as SARS-CoV-2, both during an active infection and later following a subsequent exposure. They can both also potentially contribute to pathogenesis if they are overstimulated. Despite these advances in knowledge, there are still significant gaps in understanding of what constitutes a protective or immunopathologic immune response and its durability. Significant knowledge gaps also remain pertaining to the early recognition of COVID patients with increased risk of clinical deterioration who require continued hospitalization and the use of more intensive treatments designed to improve outcomes. Data from non-COVID patients with MI show that platelet surface expression of FcγRIIa, the low-affinity receptor for the Fc fragment of immunoglobulin (Ig) G, identifies patients at high and low risk of subsequent cardiovascular events. Platelet expression of FcγRIIa is increased by interferon γ20 that is significantly elevated in severe COVID-19 infections. The high prevalence of arterial thrombosis among COVID-19 patients and the central role of thrombosis in respiratory failure support the hypothesis that elevated platelet expression of FcγRIIa will identify COVID patients at increased risk of thrombotic complications and clinical deterioration. In addition to the potential role of platelet activation in thrombosis associated with COIVD-19, the endothelium may also play a significant role. The investigators hypothesize that elevated EMPs in plasma will identify patients at high risk of thrombosis and clinical deterioration. To begin to address the knowledge gaps above and obtain preliminary data for future large grant submission, the investigators propose a small, prospective, single-center cohort study that will enroll patients hospitalized for COVID-19 infection and exhibiting a range of disease severity. Biosamples will be obtained and used to study T and B cells, antibody repertoire, and durability of protective immunity, and also to quantify platelet expression of FcγRIIa and circulating EMPs, as described in the protocol. Type: Observational Start Date: Feb 2021 |
A Study of Ad26.COV2.S in Healthy Pregnant Participants (COVID-19)
Janssen Vaccines & Prevention B.V.
COVID-19 Prevention
The purpose of this study is to assess the safety and reactogenicity of Ad26.COV2.S
administered intramuscularly (IM) as a 1-dose schedule at the standard dose level in adult
participants during the second and/or third trimester of pregnancy and (potentially)
post-partum;... expand
The purpose of this study is to assess the safety and reactogenicity of Ad26.COV2.S administered intramuscularly (IM) as a 1-dose schedule at the standard dose level in adult participants during the second and/or third trimester of pregnancy and (potentially) post-partum; to assess the humoral immune response in peripheral blood of adult participants to Ad26.COV2.S administered IM as a 1-dose schedule during the second and/or third trimester of pregnancy, 28 days after vaccination. Type: Interventional Start Date: Aug 2021 |
COVID-19 Associated Lymphopenia Pathogenesis Study in Blood
National Institute of Allergy and Infectious Diseases (NIAID)
Coronavirus Disease 2019
Background:
COVID-19 is an acute respiratory syndrome. One symptom of COVID-19 is a reduction in the
number of cells called lymphocytes in the blood. Lymphocytes are a type of white blood cell
that fights infections. With fewer lymphocytes, the body cannot effectively fight... expand
Background: COVID-19 is an acute respiratory syndrome. One symptom of COVID-19 is a reduction in the number of cells called lymphocytes in the blood. Lymphocytes are a type of white blood cell that fights infections. With fewer lymphocytes, the body cannot effectively fight back against SARS CoV-2, the virus that causes COVID-19. Researchers want to better understand how SARS-CoV-2 affects these blood cells. This information may give them ideas for new treatments. Objective: To learn more about how SARS-CoV-2 affects lymphocytes, the immune, and the blood clotting system. Eligibility: Adults age 18 and older who either currently have COVID-19 or have recently recovered from it Design: Participants will give a blood sample. For this, a needle is used to collect blood from an arm vein. For participants who have a central line, blood will be collected through that instead. Participants medical records related to COVID-19 will be reviewed. Participants who have recovered from COVID-19 will be asked to undergo leukapheresis to collect white blood cells. For this, blood is taken from a needle placed in one arm. A machine separates out the white blood cells. The rest of the blood is returned to the participant through a needle placed in the other arm. This takes about 2-3 hours. Recovered participants may have material collected from inside the nostrils and/or rectum. This is done by gently rubbing the area with a sterile cotton swab. Recovered participants may have an echocardiogram to look at their heart. For this, a small probe is held against the chest to get pictures of the heart from different angles. This takes less than 30 minutes. Participation lasts 1-2 days on most cases and may be split in a few visits for recovered patients if leukapheresis and echocardiogram are done. ... Type: Observational Start Date: May 2020 |
Community Care Intervention to Decrease COVID-19 Vaccination Inequities
RAND
COVID-19 Vaccination
The purpose of this study is to find out if a community health workers (CHW) intervention
conducted in Federally Qualified Health Centers (FQHCs) can increase the number of adults
with chronic illnesses who are up-to-date with their COVID-19 and influenza vaccines.
expand
The purpose of this study is to find out if a community health workers (CHW) intervention conducted in Federally Qualified Health Centers (FQHCs) can increase the number of adults with chronic illnesses who are up-to-date with their COVID-19 and influenza vaccines. Type: Interventional Start Date: Sep 2023 |
Vale+Tú Salud: Corner-Based Randomized Trial to Test a Latino Day Laborer Program Adapted to Prevent...
The University of Texas Health Science Center, Houston
COVID-19
The purpose of this study is to assess the extent to which LDL report increased adherence
with COVID 19 mitigation practices 1 month post intervention.
expand
The purpose of this study is to assess the extent to which LDL report increased adherence with COVID 19 mitigation practices 1 month post intervention. Type: Interventional Start Date: Nov 2023 |
Social Determinants of Health in Patients With Penetrating Trauma Injuries Before and During the COVID-19...
Kern Medical Center
Penetrating Injury
COVID-19
Social Determinants of Health
Investigators report on the impact of the COVID-19 stay-at-home order concerning penetrating
violence and its association within different socioeconomic regions within the county. The
distribution and volume of violent offenses prior to the stay-at-home order was compared to... expand
Investigators report on the impact of the COVID-19 stay-at-home order concerning penetrating violence and its association within different socioeconomic regions within the county. The distribution and volume of violent offenses prior to the stay-at-home order was compared to during the stay-at-home order. This bears a crucial significance in our injury prevention and education efforts within our community. Type: Observational Start Date: Mar 2019 |
Connecting Friends and Health Workers to Boost COVID-19 Vaccination in Latino Communities
Johns Hopkins University
COVID-19
Vaccine
The goal of this clinical trial is to find out which approach works better in getting more of
the friends and connections of Latino adults get vaccinated against COVID-19.
The main questions this study aims to answer are:
1. Can teaching people to use motivational interviewing... expand
The goal of this clinical trial is to find out which approach works better in getting more of the friends and connections of Latino adults get vaccinated against COVID-19. The main questions this study aims to answer are: 1. Can teaching people to use motivational interviewing help more friends and connections of Latino adults get the COVID-19 vaccine compared to just giving information about the vaccine? 2. What are the things that make it easier or harder for Latinos and networks to get the COVID-19 vaccine? 3. How does this intervention work in practice so that it can be made available to more people in the future The researchers will compare the vaccine rates of the friends and connections of Latinos who have been trained in motivational interviewing with those who have only been given information about the COVID-19 vaccine. This will help figure out which method works best to encourage more people to get vaccinated. Type: Interventional Start Date: Jul 2023 |
Exercise Interventions in Post-acute Sequelae of Covid-19
University of Virginia
COVID-19
The COVID-19 pandemic severely impacted the medical system both directly but also through
incomplete recovery from the virus in the form of post-acute sequelae of COVID-19 (PASC).
PASC affects at least 9.6 million individuals as of May 2022 and continues to affect many
more.... expand
The COVID-19 pandemic severely impacted the medical system both directly but also through incomplete recovery from the virus in the form of post-acute sequelae of COVID-19 (PASC). PASC affects at least 9.6 million individuals as of May 2022 and continues to affect many more. PASC is a multisystem disorder often presenting with mental fog, dyspnea on exertion, and fatigue among other symptoms. The etiology of PASC is uncertain but theories include direct cytotoxicity, dysregulated immune responses, endotheliitis associated with microthrombi, eNOS uncoupling, and myocardial fibrosis with impaired ventricular compliance. To date, there are no established treatments. Exercise has the potential as a therapeutic option to improve VO2peak and improve each of the aforementioned underlying etiologies. The investigators plan to examine the effect of High-Intensity Interval Training (HIIT) and Moderate intensity exercise training (MOD) on the symptoms and exercise tolerance of patients with PASC. The investigators approach will consist of a randomized, blinded, 2-arm, parallel-group design. Enrolled subjects will be randomly assigned to one of two groups in a 1:1 allocation ratio. All groups will undergo a 4-week intervention of 3 days of HIIT per week and 2 days of MOD per week or control of light stretching and controlled breathing. Subjects will be assessed before and after the 4-week intervention to examine the extent to which 4 weeks of the HIIT and MOD combination improves VO2peak and left ventricular diastolic function, global longitudinal strain (GLS), and global circumferential strain (GCS). Further, the investigators will explore changes in markers such as heart rate, heart rhythm, blood pressure, quality of life, exercise tolerance, and PASC symptoms as well as blood/serum markers. Type: Interventional Start Date: Sep 2023 |
A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals
BioNTech SE
SARS-CoV-2 Infection
COVID-19
The purpose of this clinical protocol is to learn about the safety, tolerability, and
immunogenicity of new BNT162b2 RNA-based vaccine candidates targeting new variants of
SARS-CoV-2 in healthy people.
Substudy A:
- This study will evaluate the safety, tolerability,... expand
The purpose of this clinical protocol is to learn about the safety, tolerability, and immunogenicity of new BNT162b2 RNA-based vaccine candidates targeting new variants of SARS-CoV-2 in healthy people. Substudy A: - This study will evaluate the safety, tolerability, and immunogenicity of BNT162b2 (Omi XBB.1.5) given as a single 30 µg dose, - in people who are 12 years of age and older, - who previously received at least 3 doses of a US-authorized mRNA COVID-19 vaccine, with the most recent dose being an Omicron BA.4/BA.5-adapted bivalent vaccine received at least 150 days before the study vaccination (Visit 1). - The study is about 6 months long for each participant. - Participants will have at least 5 visits to the clinic. - At each clinic visit a blood sample will be taken. - At least 1 nasal swab will taken. Substudy B: - This study will evaluate the safety, tolerability, and immunogenicity of BNT162b2 (Omi XBB.1.5) given as a single 30 µg dose, - in people who are 12 years of age and older, - who are COVID-19 vaccine-naïve - who have had any positive SARS-CoV-2 test result >28 days before study vaccine administration. - The study is about 6 months long for each participant. - Participants will have at least 5 visits to the clinic. - At each clinic visit a blood sample will be taken. - At least 1 nasal swab will taken. Type: Interventional Start Date: Aug 2023 |
Study of Obeldesivir in Children and Adolescents With COVID-19
Gilead Sciences
COVID-19
The goal of this clinical study is to learn more about the safety and tolerability of
obeldesivir (ODV) in children and adolescents with coronavirus disease 2019 (COVID-19).
The primary objectives are to evaluate the plasma pharmacokinetics (PK), safety and
tolerability... expand
The goal of this clinical study is to learn more about the safety and tolerability of obeldesivir (ODV) in children and adolescents with coronavirus disease 2019 (COVID-19). The primary objectives are to evaluate the plasma pharmacokinetics (PK), safety and tolerability of ODV in pediatric participants with COVID-19. Type: Interventional Start Date: Nov 2023 |
A Safety and Immune Response Study to Evaluate Varying Doses of an mRNA Vaccine Against Coronavirus Disease...
GlaxoSmithKline
COVID-19
The purpose of this study is to evaluate the safety, reactogenicity and immune responses of
the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA-CR-04 vaccine construct
when administered in healthy adults previously vaccinated with SARS-CoV-2 mRNA vaccines.... expand
The purpose of this study is to evaluate the safety, reactogenicity and immune responses of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA-CR-04 vaccine construct when administered in healthy adults previously vaccinated with SARS-CoV-2 mRNA vaccines. Type: Interventional Start Date: Aug 2023 |
Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines
Novavax
COVID-19
This is a Phase 2/3, randomized, double-blind study to evaluate the safety and immunogenicity
of different booster dose levels of the monovalent severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) recombinant (r) spike (S) protein nanoparticle (SARS-CoV-2 rS)
vaccines... expand
This is a Phase 2/3, randomized, double-blind study to evaluate the safety and immunogenicity of different booster dose levels of the monovalent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recombinant (r) spike (S) protein nanoparticle (SARS-CoV-2 rS) vaccines with Matrix-M™ adjuvant (NVX-CoV2373 [prototype Wuhan vaccine with Matrix-M adjuvant] or NVX-CoV2601 [Omicron XBB.1.5 subvariant vaccine with Matrix-M adjuvant]). Type: Interventional Start Date: Oct 2023 |
Effectiveness and Use of COVID-19 Vaccines Using Information From the California State Vaccine Registry
Pfizer
SARS-CoV-2
COVID-19
Post-Acute COVID-19 Syndrome
This study aims to use vaccination information from the California Immunization Registry
linked with HealthVerity insurance claims for patients residing in California for the
following:
- to measure effectiveness of the Pfizer-BioNTech bivalent booster against post-COVID... expand
This study aims to use vaccination information from the California Immunization Registry linked with HealthVerity insurance claims for patients residing in California for the following: - to measure effectiveness of the Pfizer-BioNTech bivalent booster against post-COVID conditions. - to understand characteristics of patients who are receiving COVID-19 vaccines. All patients who have been de-identified in the HealthVerity database are eligible to be included for both aims of this study. Type: Observational Start Date: Oct 2023 |
Study of VXCO-100, a SARS-CoV Candidate Vaccine in Healthy Adults in the United States
Vaccine Company, Inc.
SARS-CoV
SARS-CoV-2
The purpose of this study is to evaluate the safety and immunogenicity of ascending dose
levels of VXCO-100 in healthy adults.
expand
The purpose of this study is to evaluate the safety and immunogenicity of ascending dose levels of VXCO-100 in healthy adults. Type: Interventional Start Date: May 2023 |
RADx-UP- Impact of Community Health Worker Deployment
Morehouse School of Medicine
Diabetes
COVID-19
Community Health Workers
Health Behavior
Health Knowledge, Attitudes, Practice
The proposed project will implement and evaluate a brief Community Health Worker (CHW)
intervention through the Albany Area Primary Health Care, a rural Federally Qualified Health
Center (FQHC). The primary goal of this study is to maximize effective outreach, education,
and... expand
The proposed project will implement and evaluate a brief Community Health Worker (CHW) intervention through the Albany Area Primary Health Care, a rural Federally Qualified Health Center (FQHC). The primary goal of this study is to maximize effective outreach, education, and communication through CHWs in order to facilitate improved COVID-19 vaccine confidence and uptake in underserved and vulnerable communities. CHWs will be deployed to the homes of adults with increased risk of morbidity and mortality (i.e., African Americans or Latinos with uncontrolled diabetes or prediabetes, age <50 years, and non-COVID-19 vaccinated) in order to educate them about diabetes, COVID-19 and related vaccines. Health assessments, including blood glucose measurement, will be conducted on the indexed patient and offered to all other adult family members in the household (i.e., "bubble"). Adults with Type 2 diabetes likely live in households with other adults who have or are at increased risk for diabetes (i.e., prediabetes and obesity).1 It is expected that they will also share similar COVID-19 exposure risk. The specific aims are to: 1) Evaluate a community-driven education program to increase and enhance COVID-19 vaccine confidence and uptake in individuals with uncontrolled diabetes and their families (i.e., their "bubble") and 2) Evaluate a community-driven education program to improve diabetes self-management behaviors and related outcomes (e.g., blood glucose) in individuals with uncontrolled diabetes in rural, Southwest Georgia. Type: Interventional Start Date: Feb 2022 |
Arginine Replacement Therapy in COVID-19
Emory University
COVID-19
The purpose of this study is to investigate if receiving doses of arginine (a protein in the
body) will improve mitochondria function in children with COVID-19.
The study will be performed in Children's Healthcare of Atlanta, Egleston campus. Patients
will be randomized... expand
The purpose of this study is to investigate if receiving doses of arginine (a protein in the body) will improve mitochondria function in children with COVID-19. The study will be performed in Children's Healthcare of Atlanta, Egleston campus. Patients will be randomized to receive one of three doses of arginine three times a day for five days or at discharge whichever comes first. Type: Interventional Start Date: Dec 2023 |
Strategies and Treatments for Respiratory Infections &Amp; Viral Emergencies (STRIVE): Immune Modulation...
University of Minnesota
COVID-19
COVID-19 can trigger a dysregulated immune response, and previous studies have shown that
immune modulation can improve outcomes in hospitalized patients. This trial is designed to
determine whether intensification of immune modulation early in the course of the disease
(while... expand
COVID-19 can trigger a dysregulated immune response, and previous studies have shown that immune modulation can improve outcomes in hospitalized patients. This trial is designed to determine whether intensification of immune modulation early in the course of the disease (while patients are on low flow oxygen) with abatacept (active arm) combined with standard of care (SOC) improves recovery as compared with placebo + SOC (placebo arm). For both groups, intensification of immunomodulation will be provided as part of SOC in case of signs of disease progression (patient requires high flow nasal oxygen (HFNO) or more support) and/or if the patient has rapidly increasing oxygen requirement. Type: Interventional Start Date: Jul 2023 |
A Study to Understand the Effect and Safety of the Study Medicine PF-07817883 in Adults Who Have Symptoms...
Pfizer
SARS-CoV-2 Infection
The purpose of the study is to understand the effects and safety of PF-07817883 treatment.
The study wants to know how PF-07817883 treatment lowers the level of the virus that causes
COVID 19. To understand that samples are collected from adult participants who have the
symptoms... expand
The purpose of the study is to understand the effects and safety of PF-07817883 treatment. The study wants to know how PF-07817883 treatment lowers the level of the virus that causes COVID 19. To understand that samples are collected from adult participants who have the symptoms of COVID 19 but are not hospitalized. The study is seeking for participants who: - are 18 years of age or older at the time of entering the study. - have a positive rapid antigen test within 48 hours before entering the study. Rapid antigen test is a test done to confirm the presence of a specific virus in the body. - have onset of signs or symptoms of COVID-19 within 5 days before entering the study. - have at least 1 of the specified signs or symptoms of COVID-19 present on the day of entering the study. Around 228 participants with a confirmed case of COVID 19 are planned to be taken into the study. Participants will be randomly grouped to receive PF-07817883. Three groups will receive 100, 300, 600mg of PF-07817883 and one of the groups will receive placebo (a pill that doesn't have any medicines) orally every 12 hours for 5 days. The study is going to last up to 5 weeks. This includes the initial period of selecting participants, participants receiving the medicine or the placebo and then a 4-week follow-up period after giving the participants the last medicine. The study team will monitor how each participant is doing with the study treatment during the study. Type: Interventional Start Date: May 2023 |
A Decentralized, Randomized Phase 2 Efficacy and Safety Study of Nirmatrelvir/Ritonavir in Adults With...
Harlan M Krumholz
Long COVID
This decentralized trial is a Phase 2, 1:1 randomized, double-blind, superiority,
placebo-controlled study in an anticipated 100 non-hospitalized highly symptomatic adult
participants with long COVID. It seeks to determine the efficacy, safety, and tolerability of
15 days... expand
This decentralized trial is a Phase 2, 1:1 randomized, double-blind, superiority, placebo-controlled study in an anticipated 100 non-hospitalized highly symptomatic adult participants with long COVID. It seeks to determine the efficacy, safety, and tolerability of 15 days of Paxlovid (nirmatrelvir/ritonavir), an anti-viral agent, compared with placebo plus ritonavir. The hypothesis is that viral persistence contributes to long COVID in some patients and nirmatrelvir/ritonavir compared with placebo/ritonavir can improve general health status in participants with long COVID. The study will also seek immune signatures associated with treatment response (overseen by Professor Akiko Iwasaki). The decentralized study does not require site visits, and participants in all 48 states including the District of Columbia, who meet entry criteria can enroll. It is designed to make it convenient to participate. The study drugs will be delivered to the participant's designated address. Long COVID is also known as post-acute sequelae of SARS-CoV-2 (PASC). Type: Interventional Start Date: Apr 2023 |
Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Rapid Panel Professional Use Product Using Mid-Turbinate...
Abbott Rapid Dx
COVID-19
Influenza A
Influenza Type B
This study is designed as an international, prospective, multicentric, clinical study to
investigate the performance of the Panbio™ COVID-19/Flu A&B Rapid Panel for the qualitative
detection of COVID-19 antigen, Influenza A antigen, and Influenza B antigen in human
mid-turbinate... expand
This study is designed as an international, prospective, multicentric, clinical study to investigate the performance of the Panbio™ COVID-19/Flu A&B Rapid Panel for the qualitative detection of COVID-19 antigen, Influenza A antigen, and Influenza B antigen in human mid-turbinate nasal swabs collected by a trained health worker. This study is part of the performance evaluation to support the CE conformity assessment procedures. Type: Interventional Start Date: Dec 2022 |
A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir)...
Pfizer
COVID-19
The purpose of this study is to learn about the safety and effects of nirmatrelvir/ritonavir
for the potential treatment of COVID-19 rebound.
The study is seeking participants who:
- Have completed treatment with nirmatrelvir/ritonavir
- Have a rebound in... expand
The purpose of this study is to learn about the safety and effects of nirmatrelvir/ritonavir for the potential treatment of COVID-19 rebound. The study is seeking participants who: - Have completed treatment with nirmatrelvir/ritonavir - Have a rebound in COVID-19 symptoms - Are SARS-CoV-2 (COVID-19) positive All study medications will be taken 2 times a day by mouth for 5 days. The first dose of study medication is taken at the study clinic and the rest at home. We will examine the experiences of people receiving the study medicines to those who do not. This will help us determine if the study medicines are safe and effective. People taking part will be in this study for about 24 weeks. Enrolled participants will need to visit the study clinic at least 8 times during the study. Type: Interventional Start Date: Oct 2022 |
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
BioNTech SE
SARS-CoV-2 Virus
Severe Acute Respiratory Syndrome Coronavirus 2
COVID-19
The purpose of this clinical trial is to learn about the safety, extent of the side effects,
and immune responses of the study vaccine (called variant-adapted BNT162b2 RNA-based vaccine)
in healthy children. The trial is divided into 5 individual studies or substudies based on... expand
The purpose of this clinical trial is to learn about the safety, extent of the side effects, and immune responses of the study vaccine (called variant-adapted BNT162b2 RNA-based vaccine) in healthy children. The trial is divided into 5 individual studies or substudies based on age group and prior history of COVID-19 vaccinations. All participants in each of the 5 sub-studies will receive study vaccine as a shot depending on what group they are in. - Substudy A design: Phase 1 includes participants 6 months through less than 4 years 3 months of age who have not received a previous coronavirus vaccination (COVID-19 vaccine naïve) and will receive 3 doses of study vaccine as their initial series, followed by a fourth dose of study vaccine. Phase 2/3 includes participants 6 months through less than 5 years of age who have not received a previous coronavirus vaccination (COVID-19 vaccine naive) and will receive 1, 2, or 3 doses of study vaccine, depending on what group they are in. - Substudy B design: includes participants 6 months through less than 5 years of age who have either received 2 or 3 prior doses of BNT162b2 and will receive study vaccine as their third or fourth dose. - Substudy C design: Phase 1 includes participants 6 months through less than 5 years of age who have received 3 prior doses of BNT162b2 and will receive study vaccine as their fourth dose. - Substudy D design: includes participants 5 through less than12 years of age who have received 2 or 3 prior doses of BNT162b2 and will receive study vaccine as their third or fourth dose. - Substudy E design: includes participants 2 through less than 12 years of age who have not received a previous coronavirus vaccination (COVID-19 vaccine naive) and will receive a single dose of study vaccine. Type: Interventional Start Date: Sep 2022 |
A Study to Learn About the Study Medicines (Nirmatrelvir Plus Ritonavir) in People Aged 12 Years or Older...
Pfizer
COVID-19
The purpose of this clinical trial is to learn about the safety and effects of the study
medicine (called Nirmatrelvir/Ritonavir) for the possible treatment of COVID-19.
Patients with COVID-19 who have more difficulty in fighting against infections have a higher
chance of... expand
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called Nirmatrelvir/Ritonavir) for the possible treatment of COVID-19. Patients with COVID-19 who have more difficulty in fighting against infections have a higher chance of severe illness. Such patients may benefit from longer treatment durations compared to the standard treatment regimen. The study is seeking participants who: - Have a confirmed COVID-19 infection - Are Immunocompromised - Experience onset of signs/symptoms attributable to the current COVID-19 infection within 5 days prior to screening and ≥1 signs/symptoms attributable to COVID-19 present on the day of randomization. In addition, this study will also evaluate the efficacy and safety of a second treatment course of nirmatrelvir/ritonavir in people who experience that their COVID-19 is flaring up within 14 days of having taken a 5-day treatment course of nirmatrelvir/ritonavir. For this group, the study is seeking participants who: - Have a confirmed COVID-19 infection - Experience a worsening of signs/symptoms after completing an initial 5-day course of nirmatrelvir/ritonavir - The worsening of COVID-19 symptoms must occur within 14 days after completion of the initial 5-day course of nirmatrelvir/ritonavir - Are Immunocompromised - Experience onset of signs/symptoms attributable to the current COVID-19 infection within 48 hours prior to screening and ≥1 signs/symptoms attributable to COVID-19 present on the day of randomization. All participants will be taking the study medicine for either 5, 10, or 15 days. The study medication will be taken by mouth 2 times a day. Participants will take part in this study for about 24 weeks. The first dose of study medication is taken at the study site and the rest at home. Selected participants will need to visit the study site at least 10 times during the study. Type: Interventional Start Date: Aug 2022 |
Computer Cognitive Training for Post-acute COVID-19 Syndrome
Nova Southeastern University
Corona Virus Infection
Cognitive Dysfunction
This study will assess the acceptability, feasibility, and impact of game-based
computer-delivered cognitive training on cognitive function in persons with cognitive
symptoms that persist after recovery from acute coronavirus-19 (COVID) infection.
expand
This study will assess the acceptability, feasibility, and impact of game-based computer-delivered cognitive training on cognitive function in persons with cognitive symptoms that persist after recovery from acute coronavirus-19 (COVID) infection. Type: Interventional Start Date: Apr 2022 |
Reparixin as add-on Therapy to Standard of Care to Limit Disease Progression in Adult Patients With COVID-19...
Dompé Farmaceutici S.p.A
Infectious Pneumonia
Severe COVID-19
Primary objective:
- To evaluate the efficacy of oral reparixin versus standard care alone in limiting disease
progression in adult patients hospitalised for infectious pneumonia acquired in the community
(CAP), including COVID-19.
Secondary objectives:... expand
Primary objective: - To evaluate the efficacy of oral reparixin versus standard care alone in limiting disease progression in adult patients hospitalised for infectious pneumonia acquired in the community (CAP), including COVID-19. Secondary objectives: - To determine the effect of reparixin on several disease severity/progression measures including recovery, ventilatory free days and mortality. Safety objectives: - To evaluate the safety of oral reparixin versus placebo in the specific clinical setting. Type: Interventional Start Date: Apr 2022 |
- Previous
- Next